Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Biohaven pharmaceutical holding company ltd. save search
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 1.15%
H: 5.99%
C: 3.17%
drug designation
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 1.15%
H: 5.99%
C: 3.17%
business financial results
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
Published: 2023-07-27 (Crawled : 15:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -17.35%
H: 2.49%
C: -6.35%
update
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
Published: 2022-09-29 (Crawled : 13:20) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.19%
H: 0.12%
C: -0.07%
als trial update sclerosis platform phase 2
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
treatment migraine positive chmp
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE
Published: 2021-12-13 (Crawled : 13:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -2.49%
H: 0.0%
C: 0.0%
nurtec approval migraine
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
Published: 2021-12-06 (Crawled : 13:30) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -5.67%
H: 0.0%
C: 0.0%
ceo
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine
Published: 2021-11-17 (Crawled : 14:30) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
treatment migraine approval
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital
Published: 2021-11-15 (Crawled : 15:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: -4.17%
platform trial als enroll
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment
Published: 2021-10-05 (Crawled : 12:15) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 3.9%
H: 2.03%
C: -3.89%
treatment migraine
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.14%
H: 2.85%
C: -0.58%
treatment europe migraine therapy
Biohaven Appoints Kishen Mehta to Board of Directors
Published: 2021-06-17 (Crawled : 23:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -0.11%
H: 2.38%
C: 1.5%
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 0.0%
H: 3.32%
C: 2.84%
presentation
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares - Mar 16, 2021
Published: 2021-03-16 (Crawled : 08:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: -4.75%
H: 3.68%
C: -2.33%
offering
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine
Published: 2021-03-10 (Crawled : 22:03) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 1.54%
H: 0.95%
C: -7.25%
israel treatment migraine approval
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
Published: 2020-12-16 (Crawled : 14:00) - biospace.com/
BHVN | News 0 d | $38.99 -7.52% 0.0% 3.4M
|
Health Technology
|
| O: 1.4%
H: 1.19%
C: -0.28%
treatment lancet
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.